A detailed history of China Universal Asset Management Co., Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 19,148 shares of NBIX stock, worth $2.65 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
19,148
Previous 19,148 -0.0%
Holding current value
$2.65 Million
Previous $2.64 Million 0.04%
% of portfolio
0.34%
Previous 0.34%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$130.4 - $143.74 $1.02 Million - $1.12 Million
7,784 Added 68.5%
19,148 $2.64 Million
Q4 2023

May 21, 2024

SELL
$106.07 - $132.76 $825,648 - $1.03 Million
-7,784 Reduced 40.65%
11,364 $1.5 Million
Q4 2023

Jan 23, 2024

BUY
$106.07 - $132.76 $939,780 - $1.18 Million
8,860 Added 353.83%
11,364 $1.5 Million
Q3 2023

May 21, 2024

BUY
$94.02 - $117.1 $115,174 - $143,447
1,225 Added 95.78%
2,504 $281,000
Q3 2023

Oct 30, 2023

BUY
$94.02 - $117.1 $115,174 - $143,447
1,225 Added 95.78%
2,504 $282,000
Q2 2023

May 21, 2024

SELL
$89.53 - $104.87 $2,685 - $3,146
-30 Reduced 2.29%
1,279 $120,000
Q2 2023

Jul 27, 2023

SELL
$89.53 - $104.87 $2,685 - $3,146
-30 Reduced 2.29%
1,279 $121,000
Q1 2023

May 21, 2024

BUY
$94.11 - $123.02 $31,244 - $40,842
332 Added 33.98%
1,309 $132,000
Q1 2023

Apr 27, 2023

BUY
$94.11 - $123.02 $31,244 - $40,842
332 Added 33.98%
1,309 $132,000
Q4 2022

May 21, 2024

SELL
$106.72 - $127.06 $1.94 Million - $2.31 Million
-18,171 Reduced 94.9%
977 $116,000
Q4 2022

Jan 31, 2023

BUY
$106.72 - $127.06 $8,644 - $10,291
81 Added 9.04%
977 $117,000
Q3 2022

Oct 21, 2022

BUY
$92.03 - $107.81 $82,458 - $96,597
896 New
896 $95,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.